Cellulitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLL003 MIFTS: 53	Cellulitis Categories: Immune diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cellulitis

MalaCards integrated aliases for Cellulitis:

Name: Cellulitis ¹¹ ⁵³ ⁴¹ ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵ ³¹

Classifications:

MalaCards categories:
Anatomical: Skin diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the skin and subcutaneous tissue

Infections of the skin and subcutaneous tissue

Cellulitis

Cellulitis, unspecified

External Ids:

Disease Ontology ¹¹ DOID:3488

MeSH ⁴³ D002481

NCIt ⁴⁹ C26715 C34454

SNOMED-CT ⁶⁸ 267833003 74276003

ICD10 ³¹ L03 L03.9

EFO ¹⁶ EFO_0003035

UMLS ⁷¹ C0007642 C0007646

Sources

Summaries for Cellulitis

MedlinePlus: ⁴¹ Cellulitis is an infection of the skin and deep underlying tissues. Group A strep (streptococcal) bacteria are the most common cause. The bacteria enter your body when you get an injury such as a bruise, burn, surgical cut, or wound. Symptoms include: Fever and chills Swollen glands or lymph nodes A rash with painful, red, tender skin. The skin may blister and scab over. Your health care provider may take a sample or culture from your skin or do a blood test to identify the bacteria causing infection. Treatment is with antibiotics. They may be oral in mild cases, or intravenous (by IV) for more severe cases.

MalaCards based summary: Cellulitis is related to orbital cellulitis and erysipelas, and has symptoms including fever, pruritus and exanthema. An important gene associated with Cellulitis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Cephalexin and Phenoxymethylpenicillin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and breast, and related phenotypes are digestive/alimentary and cardiovascular system

Disease Ontology: ¹¹ A skin disease where there is a diffuse infection of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin. Cellulitis can be caused by normal skin flora or by exogenous bacteria, and often occurs where the skin has previously been broken: cracks in the skin, cuts, blisters, burns, insect bites, surgical wounds, or sites of intravenous catheter insertion.

Wikipedia: ⁷⁵ Cellulitis is usually a bacterial infection involving the inner layers of the skin. It specifically... more...

Sources

Related Diseases for Cellulitis

Diseases related to Cellulitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1414)

#	Related Disease	Score	Top Affiliating Genes
1	orbital cellulitis	32.9	IL6 CRP CD4
2	erysipelas	31.9	TNF MYOM2 IL6 CRP
3	nocardiosis	31.9	TNF CRP CD4
4	gas gangrene	31.9	TNF IL6 CRP ALB
5	whim syndrome 1	31.7	RAC2 CSF3 CCR6
6	haemophilus influenzae	31.4	TNF LACTB
7	fasciitis	31.3	TNF MYOM2 IL6
8	cavernous sinus thrombosis	31.0	F2 CRP CD4
9	osteomyelitis	31.0	TNF IL6 CSF3 CRP
10	cryptococcosis	31.0	TNF CD4 CCR6
11	panophthalmitis	30.9	CRP CD4
12	hidradenitis	30.9	TNF CRP CAMP
13	lymphadenitis	30.9	TNF IL6 CRP CCR6
14	neutrophilic dermatosis, acute febrile	30.9	TNF CSF3 CRP
15	hidradenitis suppurativa	30.8	TNF CRP CAMP
16	maxillary sinusitis	30.8	RNASE3 LACTB CRP
17	dermatophytosis	30.8	TNF DEFB4A CD4 CCR6 CAMP
18	conjunctivitis	30.8	TNF RNASE3 IL6 IL5
19	thrombophlebitis	30.8	F2 CRP ALB
20	tinea pedis	30.8	DEFB4A CD4 CCR6 CAMP
21	intracranial abscess	30.7	LACTB CRP CD4
22	lymphangitis	30.7	FLT4 CRP CD4 ALB
23	acne	30.7	TNF IL6 DEFB4A CRP
24	endophthalmitis	30.6	TNF IL6 CRP CD4 ALB
25	pyomyositis	30.6	MYOM2 CRP CD4
26	granulomatous dermatitis	30.6	TNF CRP CD4
27	panniculitis	30.6	CSF3 CRP CD4 CCR6
28	erythema nodosum	30.6	TNF IL6 CRP
29	necrotizing fasciitis	30.6	TNF MYOM2 IL6 F2 CRP CAMP
30	liver cirrhosis	30.6	TNF IL6 F2 CHI3L1 ALB
31	dermatitis	30.5	TNF RNASE3 IL6 IL5 IGES CHI3L1
32	toxic shock syndrome	30.5	TNF MYOM2 IL6 IL1R1 CSF3 CRP
33	subdural empyema	30.5	F2 CRP
34	keratitis, hereditary	30.5	TNF IL6 CD4 CCR6
35	lemierre's syndrome	30.5	F2 CRP
36	pleural empyema	30.5	IL6 F2 CRP CD4 ALB
37	purpura	30.5	TNF IL6 F2 CRP
38	angina pectoris	30.5	TNF IL6 CRP
39	scleritis	30.5	TNF IL5 CRP CCR6
40	posterior scleritis	30.4	TNF CRP
41	neutrophilia, hereditary	30.4	IL6 CSF3 CRP
42	folliculitis	30.4	TNF IL5 DEFB4A CD4 CCR6
43	pyoderma gangrenosum	30.4	TNF IL1R1 CSF3 CHI3L1 CCR6
44	vascular disease	30.4	TNF IL6 F2 CRP ALB
45	acquired immunodeficiency syndrome	30.3	TNF IL6 CRP CD4 ALB
46	pulmonary embolism	30.3	F2 CRP ANGPT2 ALB
47	peripheral vascular disease	30.3	TNF IL6 F2 CRP ALB
48	pericarditis	30.3	TNF IL6 CRP
49	otitis externa	30.3	IL6 CRP CD4
50	bursitis	30.3	TNF IL6 CRP

Graphical network of the top 20 diseases related to Cellulitis:

Sources

Symptoms & Phenotypes for Cellulitis

UMLS symptoms related to Cellulitis:

fever; pruritus; exanthema

MGI Mouse Phenotypes related to Cellulitis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.91	ALB ANGPT2 CD4 F2 FLT4 IL1R1
2	cardiovascular system	MP:0005385	9.9	ALB ANGPT2 CCR6 CRP F2 FLT4
3	immune system	MP:0005387	9.86	ALB ANGPT2 CAMP CCR6 CD4 CHI3L1
4	hematopoietic system	MP:0005397	9.44	ANGPT2 CAMP CCR6 CD4 CHI3L1 CSF3

Sources

Drugs & Therapeutics for Cellulitis

Drugs for Cellulitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cephalexin

Approved, Investigational, Vet_approved

Phase 4

15686-71-2

27447

Phenoxymethylpenicillin

Approved, Vet_approved

Phase 4

87-08-1

6869

Ceftaroline fosamil

Approved, Investigational

Phase 4

229016-73-3

72562361

Bacitracin

Approved, Vet_approved

Phase 4

1405-87-4

10909430

Retapamulin

Approved

Phase 4

224452-66-8

6918462

Copper

Approved, Investigational

Phase 4

7440-50-8

27099

Cantharidin

Approved, Investigational

Phase 4

56-25-7

2545

Flucloxacillin

Approved, Investigational

Phase 4

5250-39-5, 34214-51-2

21319

Meticillin

Approved, Investigational

Phase 4

61-32-5

6087

Vancomycin

Approved

Phase 4

1404-90-6

14969

Daptomycin

Approved, Investigational

Phase 4

103060-53-3

16129629

Dalbavancin

Approved, Investigational

Phase 4

171500-79-1

16134627

beta-Lactams

Phase 4

Lactams

Phase 4

Penicillins

Phase 4

Anti-Infective Agents, Local

Phase 4

Copper Supplement

Phase 4

Antibiotics, Antitubercular

Phase 4

Anti-Bacterial Agents

Phase 4

Anti-Infective Agents

Phase 4

Probenecid

Approved, Investigational

Phase 3

57-66-9

4911

Moxifloxacin

Approved, Investigational

Phase 3

186826-86-8, 354812-41-2, 151096-09-2

152946

Oritavancin

Approved, Investigational

Phase 3

171099-57-3

16136912

Telavancin

Approved

Phase 3

372151-71-8

21014972 3081362

Caffeine

Approved

Phase 2, Phase 3

58-08-2

2519

Mupirocin

Approved, Investigational, Vet_approved

Phase 3

12650-69-0

446596

Ciprofloxacin

Approved, Investigational

Phase 2, Phase 3

85721-33-1, 93107-08-5

2764

Levofloxacin

Approved, Investigational

Phase 2, Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 2, Phase 3

82419-36-1

4583

Imipenem

Approved

Phase 3

74431-23-5, 64221-86-9

104838

Meropenem

Approved, Investigational

Phase 3

119478-56-7, 96036-03-2

441130

Cilastatin

Approved, Investigational

Phase 3

82009-34-5

6435415

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 3

439-14-5

3016

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 3

55-56-1

2713 9552079

Ethanol

Approved

Phase 3

64-17-5

702

Fusidic acid

Approved, Investigational

Phase 3

6990-06-3

3000226

Ceftobiprole medocaril

Approved, Experimental, Investigational

Phase 3

376653-43-9

139292184

Ceftobiprole

Approved, Investigational

Phase 3

209467-52-7

139595999

Ceftazidime

Approved

Phase 3

78439-06-2, 72558-82-8

5481173

Clindamycin

Approved, Vet_approved

Phase 3

18323-44-9, 24729-96-2

29029

Metronidazole

Approved

Phase 3

443-48-1, 69198-10-3

4173

Oxacillin

Approved, Investigational

Phase 3

66-79-5

6196

Teicoplanin

Approved, Investigational

Phase 3

61036-62-2

16170201

Cefadroxil

Approved, Vet_approved, Withdrawn

Phase 3

66592-87-8, 50370-12-2

47965

Aztreonam

Approved

Phase 3

78110-38-0

5742832

Norgestimate, ethinyl estradiol drug combination

Phase 3

Vaccines

Phase 3

Cephalosporins

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Interventional clinical trials:

(show top 50) (show all 133)

#	Name	Status	NCT ID	Phase	Drugs
1	Oral Flucloxacillin Alone Versus Flucloxacillin and Phenoxymethylpenicillin for the Emergency Department Outpatient Treatment of Cellulitis: a Non-inferiority Randomised Controlled Trial.	Unknown status	NCT02922686	Phase 4	Flucloxacillin;Phenoxymethylpenicillin;Placebo (for phenoxymethylpenicillin)
2	Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence	Unknown status	NCT02566928	Phase 4	2% mupirocin ointment
3	A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis	Completed	NCT01876628	Phase 4	Flucloxacillin;Clindamycin;Placebo oral capsule
4	Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I)	Completed	NCT00552799	Phase 4	Penicillin VK
5	Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin	Completed	NCT01626560	Phase 4	Daptomycin;Vancomycin
6	High-dose Cephalexin for Cellulitis: A Pilot Randomized Controlled Trial	Completed	NCT04471246	Phase 4	Cephalexin
7	A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas	Completed	NCT00295178	Phase 4	Daptomycin;Vancomycin
8	Randomized Clinical Trial of Wound Packing Following Incision and Drainage of Superficial Skin Abscesses in the Pediatric Emergency Department	Completed	NCT00746109	Phase 4
9	Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections	Completed	NCT01549613	Phase 4	Daptomycin;Vancomycin
10	Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus	Completed	NCT02582203	Phase 4	Ceftaroline;Vancomycin
11	The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown	Completed	NCT03929224	Phase 4	Medicinal honey;Bacitracin
12	An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months	Completed	NCT00555061	Phase 4	Retapamulin Ointment, 1%
13	Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA)	Completed	NCT00352612	Phase 4	clindamycin;cephalexin
14	A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)	Completed	NCT01419184	Phase 4	Daptomycin;Vancomycin
15	Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients	Recruiting	NCT05070754	Phase 4	Canthardin Collodion
16	Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis	Terminated	NCT02032654	Phase 4	Flucloxacillin;Placebo (for flucloxacillin)
17	A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)	Terminated	NCT00463801	Phase 4	Daptomycin
18	Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI)	Terminated	NCT03372941	Phase 4	Dalbavancin
19	Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department	Unknown status	NCT00323219	Phase 3	Cefazolin and Moxifloxacin
20	A Pilot Randomized Controlled Trial Assessing the Effectiveness of Alcohol Swabs in Preventing Infections in Pediatric Patients Receiving Vaccinations	Unknown status	NCT03131843	Phase 3	Alcohol;No alcohol
21	A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections	Completed	NCT02127970	Phase 3	Dalbavancin;Dalbavancin-matching Placebo
22	Ultrasound Guided Needle Drainage Versus Formal Incision and Drainage of Superficial Soft Tissue Abscesses in the Emergency Department Setting	Completed	NCT01085929	Phase 3
23	The Effects of Iontophoresis in Women With Gynoid Hidrolipodystrophy.	Completed	NCT03556917	Phase 2, Phase 3
24	A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Levofloxacin Versus Ciprofloxacin HCl in the Treatment of Mild to Moderate Skin and Skin Structure Infections in Adults	Completed	NCT00257036	Phase 2, Phase 3	levofloxacin
25	A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections.	Completed	NCT00619710	Phase 3	Meropenem;Imipenem-cilastatin
26	A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)	Completed	NCT01252732	Phase 3	Single-Dose IV Oritavancin Diphosphate;IV Vancomycin
27	A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)	Completed	NCT01252719	Phase 3	Single-Dose IV Oritavancin Diphosphate;IV Vancomycin;Placebo
28	A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections	Completed	NCT01431339	Phase 3	IV Dalbavancin;Vancomycin/Linezolid
29	A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections	Completed	NCT01339091	Phase 3	Dalbavancin;Vancomycin / Linezolid
30	A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome	Completed	NCT00465985	Phase 3	ACZ885;Placebo
31	A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus	Completed	NCT00852540	Phase 3	Retpamulin Ointment, 1%;Linezolid
32	An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease	Completed	NCT00685373	Phase 3	Canakinumab (ACZ885)
33	A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL	Completed	NCT00684177	Phase 3	Retapamulin Ointment, 1%;Placebo ointment
34	An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo	Completed	NCT00133874	Phase 3	SB-275833 ointment, 1%
35	A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus	Completed	NCT00107978	Phase 3	Telavancin;Vancomycin
36	A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections	Completed	NCT00210899	Phase 3	ceftobiprole medocaril;Vancomycin plus Ceftazidime
37	A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections	Completed	NCT00228982	Phase 3	Ceftobiprole medocaril;Vancomycin
38	An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan	Completed	NCT00991146	Phase 3	canakinumab
39	A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus	Completed	NCT00091819	Phase 3	Telavancin;Vancomycin
40	Evaluation of Novel Antimicrobial Hand Towels	Completed	NCT02512614	Phase 2, Phase 3
41	A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care	Completed	NCT00560599	Phase 3	mupirocin and chlorhexidine;mupirocin, chlorhexidine, & household cleaning/disinfection
42	An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)	Completed	NCT01576367	Phase 3
43	A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)	Completed	NCT01302860	Phase 3	ACZ885
44	A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections	Recruiting	NCT02814916	Phase 3	Dalbavancin single dose;Dalbavancin two dose;Comparator
45	A Blinded, Non-inferiority Phase III Trial of 5 Versus 7 Days of Oral Flucloxacillin in Primary Care Patients With Lower Limb Cellulitis	Not yet recruiting	NCT05584007	Phase 3	Flucloxacillin Only Product in Oral Dose Form;Placebo Only Product in Oral Dose Form
46	Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial	Completed	NCT01029782	Phase 2	IV cefazolin plus oral probenecid and placebo cephalexin;Oral cephalexin and saline IV plus probenecid placebo
47	A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer	Completed	NCT01770509	Phase 1, Phase 2
48	Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients	Completed	NCT01519778	Phase 2	TR701 FA
49	Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)	Completed	NCT00514527	Phase 2	oritavancin
50	A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)	Completed	NCT00061633	Phase 2	Telavancin;Vancomycin or antistaphylococcal penicillin

Search NIH Clinical Center for Cellulitis

Cochrane evidence based reviews: cellulitis

Sources

Genetic Tests for Cellulitis

Sources

Anatomical Context for Cellulitis

Organs/tissues related to Cellulitis:

MalaCards : Skin, Lymph Node, Breast, Bone, Eye, Bone Marrow, Spinal Cord

Sources

Publications for Cellulitis

Articles related to Cellulitis:

(show top 50) (show all 10109)

#	Title	Authors	PMID	Year
1	Compression stockings for recurrent cellulitis. ⁶² ⁴¹	Grunwald J...Thomas B	35292457	2022
2	Diagnostic accuracy of contrast-enhanced CT for neck abscesses: A systematic review and meta-analysis of positive predictive value. ⁶² ⁴¹	Hagelberg J...Hirvonen J	36288374	2022
3	Smooth versus Textured Implant Breast Reconstruction: Patient-Reported Outcomes and Complications. ⁶² ⁴¹	Vorstenbosch J...Nelson JA	34705770	2021
4	Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. ⁵³ ⁶²	Ghalamkarpour A...Vikkula M	16965327	2006
5	Pelvic cellulitis, a rare complication of bartholinitis: report of two cases. ⁶²	Benabderrazik B...Boubbou M	36457796	2023
6	Fulminant endogenous panophthalmitis caused by Clostridium septicum infection. ⁶²	Diaz AB...Gili P	35170633	2023
7	Acute inflammatory presentation of orbital metastasis from urothelial carcinoma: a case report. ⁶²	Ghali A...Woolf S	34078220	2022
8	Orbital abscess: 20 years' experience at a tertiary eye care center. ⁶²	Alam MS...Mukherjee B	35195044	2022
9	Microbiological profile and antibiotic susceptibility trends in orbital cellulitis in India: an analysis over 15 years. ⁶²	Joseph J...Naik MN	34939530	2022
10	Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001-2019. ⁶²	Hoefler F...Allix-Beguec C	36418019	2022
11	Machine learning prediction of diabetic foot ulcers in the inpatient population. ⁶²	Stefanopoulos S...Ahmed A	34461765	2022
12	Paediatric lymphoedema: An audit of patients seen by the paediatric and primary lymphoedema group of vascular European Reference Network (VASCERN). ⁶²	Devoogdt N...Keeley V	36243335	2022
13	Contrasting presentations of the same disease: A comparison of two cases of amyloidosis presenting with eyelid involvement. ⁶²	Kim C...Yoo D	36217437	2022
14	Racial and ethnic differences in hospital admissions for cellulitis in the United States: A cross-sectional analysis. ⁶²	Zheng NS...Kerby EH	36041556	2022
15	Cellulitis due to Pasteurella stomatis and Actinomyces canis following dog bite. ⁶²	Fernandez-Vecilla D...Diaz de Tuesta-Del Arco JL	36243951	2022
16	Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. ⁶²	Soileau MJ...Hauser RA	36402160	2022
17	Effectiveness of postoperative oral administration of cephalexin and metronidazole on surgical site infection among obese women undergoing cesarean section: a randomized, double-blind, placebo-controlled, parallel-group study-phase III. ⁶²	Tara F...Moeindarbari S	36471429	2022
18	Factors Associated With Gastrostomy Tube Complications in Infants With Congenital Heart Disease. ⁶²	Tran NN...Kelley-Quon LI	36030602	2022
19	Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease. ⁶²	Xu TT...Mohney BG	34821545	2022
20	The higher incidence of cases with poor prognostic factors in breast cancer patients who developed both breast cancer-related lymphedema and cellulitis might explain higher mortality. ⁶²	Altundag K	36029290	2022
21	Monkeypox as an emerging infectious disease: the ophthalmic implications. ⁶²	Milligan AL...Dunning J	36216412	2022
22	Long-term survival analysis of free flap reconstruction in patients with collagen vascular disorders. ⁶²	Yan M...Vijayasekaran A	36274012	2022
23	International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. ⁶²	Zasowski EJ...Rybak MJ	36319943	2022
24	Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy. ⁶²	Kiuchi K...Hasegawa T	36113970	2022
25	Understanding the Prodromal Period of Necrotizing Soft Tissue Infections of the Genitalia (Fournier's Gangrene) and the Incidence, Duration, and Risk Factors Associated With Potential Missed Opportunities for an Earlier Diagnosis: A Population-based Longitudinal Study. ⁶²	Erickson BA...Polgreen PM	36006046	2022
26	Prophylactic postoperative antibiotics after emergent cesarean delivery and risk of postpartum infection or wound complication. ⁶²	Dellapiana G...Burwick RM	34008468	2022
27	Breast cancer-related lymphedema correlated with incidence of cellulitis and mortality. ⁶²	Cheng MH...Kuo CF	35960614	2022
28	Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases. ⁶²	Toda M...Ryuzaki M	36028210	2022
29	Infectious complications in adult patients with idiopathic minimal change nephrotic syndrome undergoing immunosuppressive therapy. ⁶²	Hsu CY...Lee PT	36209374	2022
30	Management patterns and outcomes of patients hospitalized with diabetic foot ulcers at one tertiary care hospital. ⁶²	Bhasin A...Galvin S	36474123	2022
31	Liposuction to improve vascular access in hemodialysis patients with arteriovenous fistulas. ⁶²	Rajput S...Sharaf B	36425251	2022
32	The arteriovenous fistula and the history of a forgotten pioneer. ⁶²	Bhuiyan I...Hsiang YN	36325314	2022
33	Omadacycline for a Carbapenem-Resistant Enterobacter cloacae-Associated Wound Infection. ⁶²	VanDuyn DC...Bajwa RPS	36340620	2022
34	Lymphoedema in advanced cancer: does subcutaneous needle drainage improve quality of life? ⁶²	Landers A...Holyoake J	31471494	2022
35	Necrotizing Soft-Tissue Infection of the Trunk Resulting From Wound Caused by a Centipede: A Case Report. ⁶²	Tanaka Y...Kato H	36350797	2022
36	Evolving antibiotic resistance in Group B Streptococci causing invasive infant disease: 1970-2021. ⁶²	Sabroske EM...Flores AR	36352262	2022
37	Institution of same-day total joint replacement at an urban safety net hospital during the COVID-19 pandemic. ⁶²	Hammerberg EM...Parry JA	36060728	2022
38	Characteristics of Venous Leg Ulcer Patients at a Tertiary Wound Care Center. ⁶²	Klein A...Fukaya E	36410701	2022
39	Uptake of breast reconstruction following mastectomy: a Gold Coast experience. ⁶²	Ho D...Chang J	35426189	2022
40	Bitten to the Bone: A Case of Anxiety-Induced Osteomyelitis. ⁶²	Rivera JA...Hernandez D	36408316	2022
41	K-wire Fixation of Closed Hand Fractures Outside the Main Operating Room Does Not Increase Infections. ⁶²	Gillis JA...Lalonde DH	36438460	2022
42	Rate of concomitant cellulitis and osteoarticular infections in a pediatric population. ⁶²	Ryan CB...Ellington M	36445357	2022
43	Cervico-thoracic cellulitis at the Yalgado Ouedraogo University Hospital: About 50 cases. ⁶²	Mathieu M...Tarcissus K	35853556	2022
44	Update on orbital vascular anomalies in pediatrics: imaging studies and management. ⁶²	Teplisky D...Sierre S	36346341	2022
45	Vascularized Lymph Node Transfer Improved Outcomes of Elderly Patients with Secondary Upper Extremity Lymphedema. ⁶²	Francis EC...Cheng MH	35780215	2022
46	Power-assisted Liposuction for Lymphedema: A Cost-utility Analysis. ⁶²	Bloom JA...Singhal D	36415620	2022
47	A Single Institution Multi-disciplinary Approach to Power-assisted Liposuction for the Management of Lymphedema. ⁶²	Granoff MD...Singhal D	33156069	2022
48	Diagnostic challenge: Diffuse large B-cell lymphoma masquerading as orbital cellulitis. ⁶²	Wen LY...Ramli NM	36380613	2022
49	Primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) simulating periorbital cellulitis. ⁶²	de Matos PR...Azevedo F	36325738	2022
50	Emergent Off-Label TAVR for Native Aortic Valve Endocarditis. ⁶²	Kalogeropoulos AS...Patterson T	36318462	2022

Sources

Genes for Cellulitis

Genes related to Cellulitis (0 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TNF	Tumor Necrosis Factor	Protein Coding	13.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	IL5	Interleukin 5	Protein Coding	12.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	CAMP	Cathelicidin Antimicrobial Peptide	Protein Coding	12.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	RNASE3	Ribonuclease A Family Member 3	Protein Coding	12.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	12.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	DEFB4A	Defensin Beta 4A	Protein Coding	11.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	CHI3L1	Chitinase 3 Like 1	Protein Coding	10.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	RAC2	Rac Family Small GTPase 2	Protein Coding	10.33	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
9	ANGPT2	Angiopoietin 2	Protein Coding	10.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
10	FLT4	Fms Related Receptor Tyrosine Kinase 4	Protein Coding	8.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16965327
11	CRP	C-Reactive Protein	Protein Coding	7.97	DISEASES inferred ¹⁴
12	LACTB	Lactamase Beta	Protein Coding	7.49	GeneCards inferred via : Publications (show sections)
13	IGES	Immunoglobulin E Concentration, Serum	Genetic Locus	7.31	GeneCards inferred via : Publications (show sections)
14	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7	DISEASES inferred ¹⁴ ¹⁴
15	ALB	Albumin	Protein Coding	6.67	DISEASES inferred ¹⁴
16	CD4	CD4 Molecule	Protein Coding	6.51	DISEASES inferred ¹⁴
17	MYOM2	Myomesin 2	Protein Coding	6.37	DISEASES inferred ¹⁴
18	IL6	Interleukin 6	Protein Coding	6.26	DISEASES inferred ¹⁴
19	CSF3	Colony Stimulating Factor 3	Protein Coding	6.19	DISEASES inferred ¹⁴
20	F2	Coagulation Factor II, Thrombin	Protein Coding	6.15	DISEASES inferred ¹⁴
21	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	6.14	DISEASES inferred ¹⁴
22	INS	Insulin	Protein Coding	6.07	DISEASES inferred ¹⁴
23	CD8A	CD8a Molecule	Protein Coding	5.97	DISEASES inferred ¹⁴
24	F3	Coagulation Factor III, Tissue Factor	Protein Coding	5.94	DISEASES inferred ¹⁴
25	CSF2	Colony Stimulating Factor 2	Protein Coding	5.8	DISEASES inferred ¹⁴
26	IL1B	Interleukin 1 Beta	Protein Coding	5.8	DISEASES inferred ¹⁴
27	IL17A	Interleukin 17A	Protein Coding	5.69	DISEASES inferred ¹⁴
28	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	5.65	DISEASES inferred ¹⁴
29	TNFSF11	TNF Superfamily Member 11	Protein Coding	5.6	DISEASES inferred ¹⁴

Sources

Variations for Cellulitis

Sources

Expression for Cellulitis

Search GEO for disease gene expression data for Cellulitis.

Sources

Pathways for Cellulitis

Pathways related to Cellulitis according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.73	ANGPT2 CCR6 CD4 CSF3 FLT4 IL1R1
2	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.66	TNF RNASE3 RAC2 IL6 IL5 IL1R1
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.52	TNF IL6 IL5 IL1R1 FLT4 F2
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.44	TNF RAC2 IL6 IL5 IL1R1 FLT4
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.17	ANGPT2 CCR6 CD4 CSF3 FLT4 IL1R1
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	12.72	TNF RAC2 IL6 IL5 IL1R1 FLT4
7	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.5	TNF IL6 F2 CD4 ANGPT2
8	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.32	TNF IL6 IL1R1 DEFB4A
9	Defensins ⁶⁶ Show member pathways Alpha-defensins ⁶⁶ Antimicrobial peptides ⁶⁶ Beta defensins ⁶⁶ Ion influx/efflux at host-pathogen interface ⁶⁶ Metal sequestration by antimicrobial proteins ⁶⁶	12.2	CAMP CCR6 CD4 DEFB4A RNASE3
10	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.83	TNF IL6 IL5 CSF3 CD4
11	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.68	IL6 CRP CD4
12	Acute viral myocarditis ⁷⁴	11.66	RAC2 IL6 CD4
13	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.65	TNF IL6 CD4
14	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.63	TNF IL6 CRP
15	Lung fibrosis ⁷⁴	11.58	TNF IL6 IL5 CSF3
16	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.54	TNF IL6 IL5
17	Innate Lymphoid Cells Differentiation ⁶⁵	11.46	TNF IL5 IL1R1 CD4 CCR6
18	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.44	TNF IL6 DEFB4A CAMP
19	Interleukin-10 signaling ⁶⁶	11.38	TNF IL6 IL1R1 CSF3
20	Development and heterogeneity of the ILC family ⁷⁴	11.25	TNF IL6 IL5
21	Immune infiltration in pancreatic cancer ⁷⁴	11.14	TNF IL6 IL5
22	Overview of nanoparticle effects ⁷⁴	10.98	TNF IL6 CRP
23	G-protein signaling_Rap2B regulation pathway ²²	10.9	TNF RAC2 IL6 IL5 FLT4 CSF3
24	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.71	IL6 IL5
25	Cytokines and inflammatory response ⁷⁴	10.48	TNF IL6 IL5 CSF3 CD4
26	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.28	TNF IL6

Sources

GO Terms for Cellulitis

Cellular components related to Cellulitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.03	TNF RNASE3 IL6 IL5 F2 DEFB4A
2	extracellular region	GO:0005576	9.77	ALB ANGPT2 CAMP CHI3L1 CRP CSF3

Biological processes related to Cellulitis according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	inflammatory response	GO:0006954	10.23	CHI3L1 CRP IL1R1 IL5 IL6 TNF
2	positive regulation of protein phosphorylation	GO:0001934	10.13	TNF FLT4 F2 CD4 CAMP
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.08	TNF IL6 IL5 CSF3
4	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.01	IL6 IL5 CSF3 CD4
5	acute-phase response	GO:0006953	9.97	IL6 F2 CRP
6	antimicrobial humoral immune response mediated by antimicrobial peptide	GO:0061844	9.97	CAMP DEFB4A F2 RNASE3
7	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	9.86	TNF IL6 IL5 F2
8	defense response to Gram-negative bacterium	GO:0050829	9.85	CAMP CD4 DEFB4A IL6 RNASE3
9	negative regulation of lipid storage	GO:0010888	9.8	TNF IL6 CRP
10	immune response	GO:0006955	9.8	TNF IL6 IL5 IL1R1 DEFB4A CSF3
11	defense response to Gram-positive bacterium	GO:0050830	9.4	TNF RNASE3 IL6 DEFB4A CRP CAMP